secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001104659-25-044792
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana cuts workforce ~55%, eliminates internal pipeline, extends cash runway to mid-2026
--------------------------------------------------------------------------------

- Workforce reduction of approx. 55% across functions; substantially complete by Q3 2025.
- Company eliminates internal pipeline development; focuses Emi-Le (B7-H4 ADC) on breast cancer.
- Estimated restructuring costs of $4-5M for severance, benefits, and outplacement.
- Cash runway extended to mid-2026 through cost-saving initiatives.
- Conference call on May 15 to discuss business updates and Q1 2025 financial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/0001104659-25-044792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/tm2514089d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer